Why most peptides are not FDA approved

Most peptides are not FDA approved, and the reason is almost always economic rather than scientific. The FDA has approved a handful of peptide medicines, including semaglutide, tirzepatide, liraglutide, and tesamorelin, for specific conditions. Hundreds of other peptides with published research, some with decades of study behind them, are not FDA approved and likely never will be.

This is the question almost every person researching peptides hits eventually. Bringing a drug through the FDA approval process costs between $500 million and $2 billion and takes ten to fifteen years. A pharmaceutical company will only spend that much on a molecule it can patent, because the patent gives the company roughly twenty years of exclusive sales to recoup the investment. Most peptides cannot be patented, because they are naturally occurring in the body or were first described in scientific literature decades ago. Anyone can synthesize them. No patent means no commercial sponsor, which means no large clinical trial program, which means no FDA approval.

The peptides that did reach FDA approval, like semaglutide and tirzepatide, are patentable modifications of naturally occurring hormones. The modification is what made the commercial case work, not the underlying biology. A patent could be put on the modified molecule, so a company could fund the trials, so the trials happened, so FDA approval followed.

This is the single most important thing to understand before reading about any specific peptide. "Not FDA approved" does not usually mean "does not work" or "is not safe." It usually means no company had a patent strong enough to pay for the trial. Many of these compounds are legally prescribed today by physicians through specialty pharmacies. The FDA Status Tracker shows the current regulatory state of every peptide PSI covers.